Reference number
1819-H

SPECIALTY QUANTITY LIMIT PROGRAM

RYDAPT (midostaurin)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	FDA-recommended dosing	Standard Limit
Rydapt 25 mg capsules	Acute myeloid leukemia: • Induction: 50 mg orally twice daily on Days 8 to 21 of each cycle with cytarabine and daunorubicin • Consolidation: 50 mg orally twice daily on Days 8 to 21 of each cycle with high-dose cytarabine Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL): • 100 mg orally twice daily	224 per 28 days

III. REFERENCES

1. Rydapt [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2017.